Skip to main content
Premium Trial:

Request an Annual Quote

NIH to Spend $43M for 2014 Shared Instrument Program

NEW YORK (GenomeWeb News) – The National Institutes of Health expects to award $43 million in 2014 to help research centers buy new or upgrade existing instruments for use in genomics, mass spectrometry, imaging, microscopy, and a range of other biomedical research areas.

The funding from NIH's Shared Instrumentation program will support the purchase or upgrading of expensive instruments through roughly 85 new awards.

These grants will provide funding of at least $100,000 and up to $600,000, although there is no limit on the total cost of the instruments the grants are used to buy.

The program, run by NIH's Office of Research Infrastructure Programs, was created to make it possible for institutions to buy expensive research tools that are necessary for NIH-funded biomedical science projects but which can only be justified on a shared-use basis.

Institutes may use these awards to help them buy instruments such as DNA and protein sequencers, mass spectrometers, electron and confocal microscopes, biosensors, cell sorters, and x-ray diffractometers.

NIH also will consider applications for stand-alone computer clusters and storage systems, but only if the instruments are solely dedicated to the research needs of a broad community of NIH-funded researchers.

NIH plans to begin accepting applications for the Shared Instrumentation Award grants in February 2013.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.